uniQure N.V. (NASDAQ:QURE – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $24.85, but opened at $28.75. uniQure shares last traded at $28.2020, with a volume of 1,190,591 shares traded.
Wall Street Analysts Forecast Growth
QURE has been the topic of several research reports. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. Chardan Capital raised their price objective on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Finally, Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $11.00 to $35.00 in a report on Monday, March 9th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average price target of $42.83.
Get Our Latest Analysis on uniQure
uniQure Price Performance
uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. Sell-side analysts anticipate that uniQure N.V. will post -3.68 EPS for the current fiscal year.
Insider Transactions at uniQure
In other news, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares in the company, valued at $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Walid Abi-Saab sold 45,000 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. This represents a 20.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 75,801 shares of company stock worth $1,406,757. Corporate insiders own 4.79% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of QURE. State Street Corp increased its stake in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. increased its position in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after purchasing an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC increased its position in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC increased its position in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new stake in uniQure during the 4th quarter worth about $33,062,000. 78.83% of the stock is owned by hedge funds and other institutional investors.
About uniQure
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Featured Articles
- Five stocks we like better than uniQure
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
- Palomar’s High-Risk Insurance Strategy Is Paying Off Big
- Marvell’s Pullback May Be the Setup Bulls Were Waiting For
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
